WAYNE, Pa., April 26, 2017 /PRNewswire/ -- Egalet
Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated
specialty pharmaceutical company focused on developing,
manufacturing and commercializing innovative treatments for pain
and other conditions, today announced it will host an investor
event on Wednesday, May 10, 2017 in
New York City, at which time the
company will release its first quarter 2017 earnings results.
Egalet will moderate a discussion with leading healthcare
providers who will discuss treating individuals living with pain in
today's environment. Egalet management will provide an overview of
the company's commercial, regulatory and business development
activities, and review first quarter financial results.
Presentations will be webcast live starting at 12:45 p.m. EDT at
http://egalet.investorroom.com/eventsandwebcasts. A replay
and transcript of the webcast will be available shortly after the
event.
About Egalet
Egalet, a fully integrated specialty pharmaceutical company, is
focused on developing, manufacturing and commercializing innovative
treatments for pain and other conditions. Egalet has three approved
products: ARYMO™ ER (morphine sulfate) extended-release tablets for
oral use only –CII, developed using Egalet's proprietary Guardian™
Technology, OXAYDO® (oxycodone HCI, USP) tablets for
oral use only –CII and SPRIX® (ketorolac tromethamine)
Nasal Spray. Using Guardian Technology Egalet is developing a
pipeline of clinical-stage, product candidates including
Egalet-002, an abuse-deterrent, extended-release, oral oxycodone
formulation for the management of pain severe enough to require
daily, around-the-clock, long-term opioid treatment and for which
alternative treatment options are inadequate. Guardian Technology
can be applied broadly across different classes of pharmaceutical
products and can be used to develop combination products that
include multiple active pharmaceutical ingredients with similar or
different release profiles. For full prescribing information on
ARYMO ER, including the boxed warning and medication guide, please
visit arymoer.com. For full prescribing information on SPRIX,
including the boxed warning and medication guide, please visit
sprix.com. For full prescribing information on OXAYDO, including
the boxed warning and medication guide, please visit oxaydo.com.
For additional information on Egalet, please visit
egalet.com.
Investor and Media Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: bcs@egalet.com
Tel: 917-432-9275
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/egalet-to-report-first-quarter-2017-financial-results-during-investor-day-on-may-10-2017-in-new-york-300445720.html
SOURCE Egalet Corporation